Most Read Articles
Rachel Soon, 6 days ago

On 8 August, the first town hall held by the Ministry of Health (MOH) with members of the pharmacy profession took place in Putrajaya. Over 500 pharmacists from across the country and from different areas of practice—community and hospital, public and private, academy and industry—converged to fill the auditorium for the chance to engage in direct dialogue with MOH.

Jackey Suen, 08 Oct 2018

Adding pertuzumab to trastuzumab plus an aromatase inhibitor (AI) improves progression-free survival (PFS) in patients with HER2-positive metastatic or locally advanced breast cancer, the phase II PERTAIN study has shown.

05 Aug 2019
Use of alpha blockers in the treatment of hypertension in women is associated with an increased risk of hypotension and related events as compared with other blood pressure-lowering drugs, as reported in a recent study.
Dr. Bryan Li, Dr. Gerry Kwok, Dr. Thomas Yau, 07 Aug 2019

Case 1: A 59-year-old gentleman with advanced HCC was referred to our centre for management. He had a history of diabetes, hypertension and ischaemic heart disease. He was a nondrinker and not a carrier of hepatitis B or C.

Case 2: A 65-year-old man with a history of alcoholic cirrhosis and oesophageal varices was found to have rising AFP levels on routine follow-up. He also had a 3-year history of diabetes and was on diet control, with an HbA1c of 6.2 percent and fasting glucose of 6.8 mmol/L. He did not need any diabetic medications.

Oral–topical treatment regimen an attractive alternative to prednisone in bullous pemphigoid

27 Jan 2019

A treatment regimen containing oral tetracycline and nicotinamide plus topical clobetasol appears to be effective in the treatment of bullous pemphigoid (BP), yielding better survival rates compared with prednisone, according to a study.

The 3-year retrospective study included 106 patients with newly diagnosed BP (mean age 78 years; 64.4 percent female), among whom 59 received tetracycline 1.5 g/daily, nicotinamide 1.2 g/daily and 0.05 percent lesionally administered clobetasol cream (TNC arm), while 47 received prednisone 0.5 mg/kg daily.

Both patient groups achieved median time to disease control after 7 days. The proportion of patients who achieved disease control at week 4 was 93.2 percent in the TNC arm vs 89.1 percent in the prednisone arm.

The median period between complete remission and relapse was 60 days in the TNC group and 90 days in the prednisone group (p=0.84). Within 1 year, significantly more patients in the prednisolone vs TNC group had at least one relapse within 1 year (50 percent vs 32.1 percent; p=0.09).

The 1-year survival was 83 percent in the TNC group and 65.9 percent in the prednisone group (p=0.04), while the corresponding 3-year survival was 71.2 percent and 48 percent (p=0.019).

The present data show that combined treatment with tetracycline, nicotinamide and lesionally administered clobetasol may improve survival rates compared with prednisone in patients with BP, researchers said. Thus, it would be reasonable to initiate this regimen in age-advanced patients with comorbidities and movement difficulties.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 6 days ago

On 8 August, the first town hall held by the Ministry of Health (MOH) with members of the pharmacy profession took place in Putrajaya. Over 500 pharmacists from across the country and from different areas of practice—community and hospital, public and private, academy and industry—converged to fill the auditorium for the chance to engage in direct dialogue with MOH.

Jackey Suen, 08 Oct 2018

Adding pertuzumab to trastuzumab plus an aromatase inhibitor (AI) improves progression-free survival (PFS) in patients with HER2-positive metastatic or locally advanced breast cancer, the phase II PERTAIN study has shown.

05 Aug 2019
Use of alpha blockers in the treatment of hypertension in women is associated with an increased risk of hypotension and related events as compared with other blood pressure-lowering drugs, as reported in a recent study.
Dr. Bryan Li, Dr. Gerry Kwok, Dr. Thomas Yau, 07 Aug 2019

Case 1: A 59-year-old gentleman with advanced HCC was referred to our centre for management. He had a history of diabetes, hypertension and ischaemic heart disease. He was a nondrinker and not a carrier of hepatitis B or C.

Case 2: A 65-year-old man with a history of alcoholic cirrhosis and oesophageal varices was found to have rising AFP levels on routine follow-up. He also had a 3-year history of diabetes and was on diet control, with an HbA1c of 6.2 percent and fasting glucose of 6.8 mmol/L. He did not need any diabetic medications.